![](/images/graphics-bg.png)
HER2neu and α-methylacyl coemzyme A racemase overexpression in prostatic cancer as indicators for prognosis
Author
Source
Journal of Babylon University : Journal of Applied and Pure Sciences
Issue
Vol. 26, Issue 1 (31 Jan. 2018), pp.261-271, 11 p.
Publisher
Publication Date
2018-01-31
Country of Publication
Iraq
No. of Pages
11
Main Subjects
Abstract EN
prostatic cancer is a malignant neoplasm characterized by elevated level 7-8 folds in both mRNA and protein levels during tumorigenesis of the prostate.
Also, HER2/neu expression could be detected in prostatic intraepithelial neoplasia (PIN) ,It affects androgen receptor function and the progression of prostatic cancer and the determination of Association between HER2/neu and α-methylacyl coemzyme A racemase (AMACR) overexpressions in prostatic cancer as prognostic factors.
This study included 50 patients aged from 50- < 70 years and 10 healthy men as control group matched with patient group ages.
Then, paraffin-embedding procedure was prepared on tissues biopsy and then, hematoxylin and eosin staining (H.
and E.
staining) procedure was done .
Finally, immunohistochemical procedure is done on both control cases and prostate cancer blocks.
This immunohistochemical procedure detects her2/neu and AMACR overexpression according to DAKO protocol scoring system.
The study showed that there is no significant difference in ages (P >0.05) between prostatic cancer patient and control group (68.46±6.26 years , 62.79±8.68 years) respectively and the prostatic cancer is more prevalence in ages >69 years old which represent 56% of cases.
Also, the overexpression of AMACR represent weak positive (46%), moderate positive (34%), strong (20%) overexpressions.
While, the overexpression of HER2/neu gives weak positive (60%), strong positive (40%) and the death occurred to 50% of prostatic cancer patient that have strong positive HER2/neu overexpression.
Those whose ages are more than 69 years old who have liability for prostatic cancer .
Immunohistochemical overexpressions of α-methylacyl coemzyme A racemase enzyme and HER2/neu have prognostic marker for prostatic cancer
American Psychological Association (APA)
al-Musawi, Hadi M.. 2018. HER2neu and α-methylacyl coemzyme A racemase overexpression in prostatic cancer as indicators for prognosis. Journal of Babylon University : Journal of Applied and Pure Sciences،Vol. 26, no. 1, pp.261-271.
https://search.emarefa.net/detail/BIM-1134608
Modern Language Association (MLA)
al-Musawi, Hadi M.. HER2neu and α-methylacyl coemzyme A racemase overexpression in prostatic cancer as indicators for prognosis. Journal of Babylon University : Journal of Applied and Pure Sciences Vol. 26, no. 1 (2018), pp.261-271.
https://search.emarefa.net/detail/BIM-1134608
American Medical Association (AMA)
al-Musawi, Hadi M.. HER2neu and α-methylacyl coemzyme A racemase overexpression in prostatic cancer as indicators for prognosis. Journal of Babylon University : Journal of Applied and Pure Sciences. 2018. Vol. 26, no. 1, pp.261-271.
https://search.emarefa.net/detail/BIM-1134608
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 270-271
Record ID
BIM-1134608